RNAi-mediated silencing of the Skp-2 gene causes inhibition of growth and induction of apoptosis in human renal carcinoma cells.

Hongsheng Lu, Meifu Gan, Xuequan Cao, Lanxi Chen, Zhaohui Yang, Wei Hu

Open access · greenAbstract read

In one paragraph

Article in International journal of clinical and experimental pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

0.1field-weighted citation impact, top 48% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Hongsheng LuDepartment of Pathology, Taizhou Central Hospital of Taizhou Enze Medical Group Taizhou, China.

Meifu GanDepartment of Pathology, Taizhou Hospital of Taizhou Enze Medical Group Linhai, China.

Xuequan CaoDepartment of Pathology, Taizhou Central Hospital of Taizhou Enze Medical Group Taizhou, China.

Lanxi ChenDepartment of Pathology, Taizhou Central Hospital of Taizhou Enze Medical Group Taizhou, China.

Zhaohui YangDepartment of Pathology, Taizhou Central Hospital of Taizhou Enze Medical Group Taizhou, China.

Wei HuDepartment of Radiation Oncology, Taizhou Central Hospital of Taizhou Enze Medical Group Taizhou, China.

Wenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal cancer ranks one of the most frequent causes of cancer death in the world. S-phase kinase-associated protein 2 (SKP 2) is overexpressed in human tumors and has prognostic value in many cancers including renal cancer, indicating its potential as a therapeutic target. In this study, we investigated the therapeutic potential of Skp-2 in renal cancer using the technique of RNA silencing via short hairpin RNA (shRNA). Synthetic shRNA duplexes against Skp-2 were introduced to down-regulate the expression of Skp-2 in a highly malignant renal carcinoma cell line, ACHN. The results indicated that siRNA targeting of Skp-2 could lead to an efficient and specific inhibition of endogenous Skp-2 activity. Furthermore, we found that depletion of Skp-2 caused a dramatic cell cycle arrest, followed by massive apoptotic cell death, and eventually resulted in a significant decrease in growth, viability and tumor formation in renal cancer cell lines studied.

Indexed as

ApoptosisCarcinoma, Renal CellCell Line, TumorCell ProliferationFlow CytometryGene Knockdown TechniquesHumansImmunoblottingKidney NeoplasmsReal-Time Polymerase Chain ReactionRNA InterferenceRNA, Small InterferingS-Phase Kinase-Associated ProteinsTransfectionRNA, Small InterferingS-Phase Kinase-Associated Proteinsapoptosiscell cycleRenal carcinomaRNA silencingSkp-2

Identifiers

PMID25120761

PMCPMC4128996

OpenAlexW340446214

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.